Solana

Solana Debt/EBITDA

Total Debt to EBITDA Ratio of Solana (HSDT) as of Nov 3, 2026.

Debt/EBITDA

-0.00

YoY

-81.33%

Last updated:

Total Debt to EBITDA Ratio of Solana is 2024 -0.00 . Total Debt to EBITDA Ratio of Solana was 2023 -0.00 . It decreases by -81.33% higher compared to the previous year.

The Solana Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
-0.04 USD
Jan 1, 2018
-0.52 USD
Jan 1, 2019
-0.03 USD
Jan 1, 2020
-0.01 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.01 USD
Jan 1, 2023
-0.00 USD
Jan 1, 2024
-0.00 USD
The Solana Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.00-81.33%
-0.00-35.45%
-0.01+4,190.01%
-0.00-97.48%
-0.01-75.07%
-0.03-94.84%
-0.52+1,333.63%
-0.04-92.50%
-0.48+159.25%
-0.19+14.88%
-0.16—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Solana Stock analysis

What does Solana do? Helius Medical Technologies develops and markets the PoNS device, a portable neuromodulation stimulator for neurological wellness. The company focuses on non-invasive platform technologies that enhance the brain's healing ability. The PoNS device is authorized as a class II medical device in Canada for short-term treatment of chronic balance deficits caused by mild-to-moderate traumatic brain injury, used alongside physical therapy. It delivers non-invasive neurostimulation to the tongue to induce neuromodulation. Helius Medical Technologies targets healthcare providers and rehabilitation centers that treat patients with traumatic brain injury. The company's product is designed for use in clinical settings under professional guidance, specifically for patients requiring short-term balance deficit therapy. The PoNS device is positioned as a complementary treatment within physical therapy protocols for neurological rehabilitation. The firm's revenue model is based on the sale of the PoNS device to healthcare institutions and rehabilitation facilities. These institutions purchase the device for use in their treatment programs, leveraging its non-invasive neurostimulation technology to address balance deficits in patients with mild-to-moderate traumatic brain injury. The company's focus on neurological wellness through non-invasive solutions drives its commercial strategy. Solana is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Solana stock

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Solana since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Solana with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Solana

All Key Metrics — Solana